Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

Lignende værker

• Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
  af: Badoux, Xavier C., et al.
  Udgivet: (2013)
• Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
  af: Parikh, Sameer A., et al.
  Udgivet: (2011)
• Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
  af: Thompson, Philip A., et al.
  Udgivet: (2019)
• Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
  af: Vitale, Candida, et al.
  Udgivet: (2016)
• The Addition of CD20 Monoclonal Antibodies to Lenalidomide Improves Response Rates and Survival in Relapsed/refractory patients with CLL Relative to Lenalidomide Monotherapy – The MD Anderson Cancer Center Experience
  af: Thompson, Philip A., et al.
  Udgivet: (2015)